Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DIS3 is a highly conserved ribonuclease that serves as the primary catalytic subunit of the RNA exosome complex, a multi-protein assembly responsible for the 3'-5' degradation and processing of a broad spectrum of nuclear and cytoplasmic RNAs in eukaryotic cells. DIS3 possesses both exoribonuclease activity (via its RNase II (RNB) domain) and endoribonuclease activity (via its N-terminal PIN domain), enabling it to process a wide variety of structured and unstructured RNA substrates. The exosome complex, by incorporating DIS3, plays a vital role in RNA surveillance, maturation, and turnover, affecting gene expression and cellular homeostasis. In humans, DIS3 is present mainly in the nucleus, with closely related but non-redundant paralogues (DIS3L, DIS3L2) found in the cytoplasm. Mutations in the DIS3 gene, particularly in the RNB domain, are recurrent in multiple myeloma (approximately 11% of patients) and are implicated in malignancy development, possibly via dysregulation of RNA degradation pathways. Essential for cell viability, DIS3's function intersects with cell cycle regulation, microtubule organization, and immune processes like antibody diversification. Given its central role in RNA metabolism and link to disease, DIS3 is considered a promising but challenging therapeutic target; pharmacological inhibition must be approached with caution due to its essential cellular functions.
For hypothetical or experimental modulators: inhibition of exoribonuclease or endoribonuclease activity, primarily affecting RNA decay and processing pathways
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DIS3 exosome endoribonuclease and 3'-5' exoribonuclease (DIS3).